Milestone Pharmaceuticals Shares Plunge After Q1 CARDAMYST Revenue Misses Forecast
MIST•Milestone Pharmaceuticals saw its shares plunge after first-quarter CARDAMYST revenue fell short of analysts’ consensus expectations. The disappointing product performance raises concerns about the company’s growth outlook and will likely pressure near-term valuations.
1. Revenue Shortfall Triggers Stock Decline
Milestone Pharmaceuticals’ CARDAMYST generated lower-than-expected first-quarter revenue, falling beneath the consensus forecast. The revenue shortfall prompted a steep sell-off in the company’s shares, reflecting investor concerns over its near-term growth trajectory and potential valuation headwinds.
